Pharmacological interventions for hypertension in children

Area of Science:

• Pediatric Nephrology and Cardiology
• Clinical Pharmacology
• Evidence-Based Medicine

Background:

• Pediatric hypertension is a growing concern, linked to rising obesity rates and posing risks for stroke, heart disease, and kidney damage.
• While non-pharmacological treatments are primary, many children require medication, particularly those with end-organ damage.
• Existing data on the long-term effects and optimal pharmacological treatment of hypertension in children is limited.

Purpose of the Study:

• To systematically review the dose-related effects of various antihypertensive medications in children.
• To compare monotherapy and combination therapy against placebo or other agents.
• To evaluate dose-response relationships within specific antihypertensive drug classes.

Main Methods:

• A comprehensive search of major databases (Cochrane, MEDLINE, EMBASE) was conducted for randomized controlled trials (RCTs).
• Inclusion criteria encompassed RCTs of at least two weeks duration in children with hypertension (defined as average SBP/DBP ≥ 95th percentile).
• Data extraction and risk of bias assessment were performed independently; data were summarized using random-effects models where possible.

Main Results:

• Twenty-one trials involving 3454 children were analyzed, with follow-up ranging from 3 to 24 weeks.
• Low-quality evidence indicated candesartan modestly reduced systolic and diastolic blood pressure compared to placebo.
• Other agents like telmisartan and metoprolol showed some blood pressure reduction, but no consistent dose-response was observed across drug classes; adverse events were generally minor.

Conclusions:

• Sparse data currently informs antihypertensive drug use in children, with outcomes limited to blood pressure changes, not end-organ damage.
• Candesartan is the most studied agent, with low-quality evidence suggesting a modest blood pressure-lowering effect.
• Current evidence suggests antihypertensive agents are safe for short-term use in children, but further research is warranted.